Rezolute, Inc. 8-K

What Happened
Rezolute, Inc. (RZLT) announced an interim update on its upLIFT clinical study via a press release dated June 2, 2026, disclosed under Item 7.01 (Regulation FD Disclosure) of Form 8-K. The company notes the disclosure contains forward-looking statements and cautions investors about reliance on those statements.

Key Details

• The update was announced in a press release issued June 2, 2026 (included as Exhibit 99.1 to the Form 8-K).
• Disclosure was made under Item 7.01 (Regulation FD Disclosure); the company states the information is not deemed “filed” under Section 18 of the Exchange Act.
• The filing expressly warns the poster contains forward‑looking statements and highlights that actual results may differ; Rezolute disclaims any obligation to update such statements except as required by law.

Why It Matters
This filing informs investors that Rezolute has shared new interim information about its upLIFT clinical program—information that could be relevant to the company’s development progress and investor expectations. However, the company emphasizes the provisional nature of forward‑looking statements and limits legal exposure for the disclosure, so investors should rely on finalized data and subsequent SEC filings for material changes.